(Reuters) – Endo International Plc and two other companies have agreed to pay $270.8 million to resolve class action lawsuits alleging Endo paid a generic drug manufacturer to delay launching a cheaper version of its Lidoderm painkiller patch.
https://www.teleconsulteurope.com/wp-content/uploads/2014/11/teleconsult-logo-300x124.png00Reuters: Health Newshttps://www.teleconsulteurope.com/wp-content/uploads/2014/11/teleconsult-logo-300x124.pngReuters: Health News2018-03-22 02:35:042018-03-22 02:35:04Endo, others to pay $270.8 mln to resolve Lidoderm U.S. antitrust cases